Publications by authors named "Bryce Portier"

Claim this Profile
C
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Josef Rüschoff, Michael Friedrich, Iris Nagelmeier, Matthias Kirchner, Lena M Andresen, Bryce Portier

Virchows Arch· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoplastic Cellularity Assessment in Molecular Testing.
Kelly A Devereaux, Rhona J Souers, Rondell P Graham, Bryce P Portier, Lea F Surrey

Arch Pathol Lab Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical Validation of Rare Tissues and Antigens With Low Frequency of Occurrence: Recommendations From The Anatomic Pathology Patient Interest Association (APPIA).
Robert L Lott, Peter V Riccelli, Elizabeth A Sheppard, Keith A Wharton, Eric E Walk, Bryce Portier

Appl Immunohistochem Mol Morphol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.
Jason D Merker, Kelly Devereaux, A John Iafrate, Suzanne Kamel-Reid, Annette S Kim, Bryce P Portier

Arch Pathol Lab Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole tumor section quantitative image analysis maximizes between-pathologists' reproducibility for clinical immunohistochemistry-based biomarkers.
Michael Barnes, Chukka Srinivas, Isaac Bai, Judith Frederick, Wendy Liu, Bryce Portier

Lab Invest· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M Banks, Bryce Portier

Breast Cancer Res Treat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Alana R Donaldson, Shashirekha Shetty, Zhen Wang, Christine L Rivera, Bryce P Portier

Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Benjamin C Calhoun, Bryce Portier, Zhen Wang, Eugen C Minca, G Thomas Budd

BMC Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.
Chunyan Liu, Kristi Pepper, Heather Hendrickson, Philip T Cagle, Bryce P Portier

Arch Pathol Lab Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Suzanne M Crumley, Kristi L Pepper, Alexandria T Phan, Randall J Olsen, Mary R Schwartz, Bryce P Portier

Arch Pathol Lab Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Philip T Cagle, Kirtee Raparia, Bryce P Portier

Adv Exp Med Biol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Brandon R Driver, Bryce P Portier, Dina R Mody, Michael Deavers, Eric H Bernicker

Arch Pathol Lab Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new ever-evolving paradigm.
Philip T Cagle, Randall J Olsen, Bryce P Portier, Hidehiro Takei, David W Bernard

Arch Pathol Lab Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.
Eugen C Minca, Raymond R Tubbs, Bryce P Portier, Zhen Wang, Christopher Lanigan

Cancer Genet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G T Devaraj, Bryce P Portier

Mol Cancer Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Warren Fiskus, Sunil Sharma, Jun Qi, John A Valenta, Leasha J Schaub, Bryce P Portier

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.
Bryce P Portier, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, Rajesh Singh, Mark J Routbort

Am J Clin Pathol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.
Rashmi Kanagal-Shamanna, Bryce P Portier, Rajesh R Singh, Mark J Routbort, Kenneth D Aldape

Mod Pathol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.
Parag Parekh, Sanchit Kamble, Nianxi Zhao, Zihua Zeng, Bryce P Portier

Biomaterials· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disorders.
Raymond R Tubbs, Hongwei Wang, Zhen Wang, Eugen C Minca, Bryce P Portier

Am J Clin Pathol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.
Bryce P Portier, Eugen C Minca, Zhen Wang, Christopher Lanigan, Aaron M Gruver

Oncotarget· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
Eugen C Minca, Bryce P Portier, Zhen Wang, Christopher Lanigan, Carol F Farver

J Mol Diagn· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.
Zhen Wang, Bryce P Portier, Aaron M Gruver, Son Bui, Hongwei Wang

J Mol Diagn· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.
Bryce P Portier, Zhen Wang, Erinn Downs-Kelly, Jordi J Rowe, Deepa Patil

Mod Pathol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA.
Deepa T Patil, Mary P Bronner, Bryce P Portier, Cory R Fraser, Thomas P Plesec

Diagn Mol Pathol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis